Text size :

Drugs, Nisticò (Aifa): “Accessible innovation, but sustainability must be ensured”

ADNKRONOS

November 10, 2026

Rome, Nov 10. (Adnkronos Health) – “To make therapeutic innovation increasingly accessible, Aifa must strive to translate the results of research and innovation to the patient. In all of this, we must combine two main concepts: access to innovative drugs and sustainability, deploying all tools that can guarantee this key transition.” This was stated by Robert Giovanni Nisticò, president of Aifa – Italian Medicines Agency, today in Rome, during the XXI edition of the Meridiano Sanità Forum ‘Health and life sciences: governing transitions, building the future’, the health think tank of The European House – Ambrosetti.

“A balance between access to innovation, appropriateness, and sustainability in the pharmaceutical system – Nisticò continues – can be found by promoting some fundamental concepts, linked, for example, to prevention, which must also be interpreted in a modern key through the use of big data, artificial intelligence, and genomics. The second pillar is prescriptive prevalence: trying to use drugs better, therefore the right drug for the right patient.”

“Today we are also moving into the field of biomarkers, precision medicine, or personalized medicine. Finally, we must also try to consider innovative drugs based on their value, measuring their health outcomes, without considering only the cost, but also the overall investment of the system,” concludes Nisticò.

Jiji Press

Related

Page TOP